Christian Weyer

Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.

Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA.

EKF-diagnostic GmbH engages in the development, manufacture, and distribution of medical equipment. It produces point of care analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and glycated hemoglobin. Its products include Quo-Test, Quo-Lab, Biosen, CardioChek Plus, Lactate Scout+, Hemo Control, Crematocrit Plus, Hemo Vet, and DiaSpectTM. The company was founded by Berthold Walter in 1990 and is headquartered in Barleben, Germany.

Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.

ProSciento, Inc. is a full-service clinical research organization that works with biopharma companies worldwide to support their outsourced clinical research needs. The company is based in Chula Vista, CA, and has subsidiaries in the United States. The company specializes in providing comprehensive and customized services for multinational, early development clinical trial programs for metabolic continuum diseases, including diabetes, obesity, and steatotic liver disease. ProSciento has conducted over 300 clinical projects and supported the development of many approved metabolic drugs and devices on the market. ProSciento was founded in 2003, and Marcus Hompesch has been the CEO of the company since its inception.